- Roberts, Kathryn G., Smith, Amanda M., Sim, Alistair T. R., Ashman, Leonie K., Verrills, Nicole M., McDougall, Fiona, Carpenter, Helen, Horan, Martin, Neviani, Paolo, Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Perrotti, Danilo
Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function
Controlling the cell cycle: the role of calcium/calmodulin-stimulated protein kinases I and II
Ser/thr phosphatases: the new frontier for myeloid leukemia therapy?
Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons
Basal protein phosphatase 2A activity restrains cytokine expression: role for MAPKs and tristetraprolin
A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
- Smith, Amanda M., Dun, Matthew D., Toop, Hamish, Lock, Richard B., Powell, Jason A., Thomas, Daniel, Guthridge, Mark A., Moore, Andrew, Ashman, Leonie K., Skelding, Kathryn A., Enjeti, Anoop, Verrills, Nicole M., Lee, Erwin M., Harrison, Celeste, Kahl, Richard, Flanagan, Hayley, Panicker, Nikita, Mashkani, Baratali, Don, Anthony S., Morris, Jonathan
Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia
Are you sure you would like to clear your session, including search history and login status?